The prognostic role of the pathological T2 subclassification for prostate cancer in the 2002 Tumour-Nodes-Metastasis staging system

BJU International

Volumn 102, Issue 4, 2008, Pages 438-441

  Van Oort, Inge M ^a,c   Witjes, J Alfred ^a   Kok, Dieuwertje E G ^a,b   Kiemeney, Lambertus A L M ^a   Hulsbergen Van De Kaa, Christina A ^a  

^a RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^b WAGENINGEN UNIVERSITY   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Biochemical recurrence; Prostate cancer; Radical prostatectomy; Staging

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; FOLLOW UP; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; TUMOR VOLUME;

HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; STATISTICS, NONPARAMETRIC;

EID: 47749093230     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.07611.x     Document Type: Article

References (17)

1. Whitmore WF Jr. Hormone therapy in prostatic cancer. Am J Med 1956 21 : 697 713
2. Beahrs O, Henson DE, Hutter RVP et al. AJCC Cancer Staging Manual, 4th edn. Philadelphia : Lippincott-Raven, 1992
3. Fleming ID, Cooper JS, Henson DE et al. AJCC Cancer Staging Manual, 5th edn. Philadelphia : Lippincott-Raven, 1997
4. Greene FL, Page DL, Fleming ID et al. AJCC Cancer Staging Manual, 6th edn. New York : Springer-Verlag, 2002
5. Cagiannos I, Graefen M, Karakiewicz PI et al. Analysis of clinical stage T2 prostate cancer: do current subclassifications represent an improvement? J Clin Oncol 2002 20 : 2025 30
6. Han M, Walsh PC, Partin AW, Rodriguez R. Ability of the 1992 and 1997 American Joint Committee on Cancer staging systems for prostate cancer to predict progression-free survival after radical prostatectomy for stage T2 disease. J Urol 2000 164 : 89 92
7. Ruijter ET, Miller GJ, Aalders TW et al. Rapid microwave-stimulated fixation of entire prostatectomy specimens. Biomed-II MPC Study Group. J Pathol 1997 183 : 369 75
8. Gleason DF. Histologic grading of prostate cancer: a perspective. Hum Pathol 1992 23 : 273 9
9. Bostwick DG. Staging prostate cancer - 1997. current methods and limitations. Eur Urol 1997 32 (Suppl. 3 2 14
10. Eichelberger LE, Cheng L. Does pT2b prostate carcinoma exist? Critical appraisal of the 2002 TNM classification of prostate carcinoma. Cancer 2004 100 : 2573 6
11. Quintal MM, Magna LA, Guimaraes MS, Ruano T, Ferreira U, Billis A. Prostate cancer pathologic stage pT2b (2002 TNM staging system): does it exist? Int Braz J Urol 2006 32 : 43 7
12. May F, Hartung R, Breul J. The ability of the American Joint Committee on Cancer Staging system to predict progression-free survival after radical prostatectomy. BJU Int 2001 88 : 702 7
13. Freedland SJ, Partin AW, Epstein JI, Walsh PC. Biochemical failure after radical prostatectomy in men with pathologic organ-confined disease: pT2a versus pT2b. Cancer 2004 100 : 1646 9
14. Chun FK, Briganti A, Lebeau T et al. The 2002 AJCC pT2 substages confer no prognostic information on the rate of biochemical recurrence after radical prostatectomy. Eur Urol 2006 49 : 273 8
15. Bostwick DG, Myers RP, Oesterling JE. Staging of prostate cancer. Semin Surg Oncol 1994 10 : 60 72
16. Hoedemaeker RF, Vis AN, van der Kwast TH. Staging prostate cancer. Microsc Res Tech 2000 51 : 423 9
17. Smith DS, Catalona WJ. Interexaminer variability of digital rectal examination in detecting prostate cancer. Urology 1995 45 : 70 4